Business Wire

NCEC

8.12.2021 01:03:06 CET | Business Wire | Press release

Share
NCEC and OURAY Announce Integrated Emergency Response Support for the Global Market

NCEC, the chemical experts arm of the Ricardo Group , is partnering with OURAY, a global environmental, engineering, manufacturing, and chemical services company, to offer Level One emergency response to OURAY customers, with an emphasis on the Americas and Asia-Pacific regions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005770/en/

OURAY’s customers will receive vital telephone-based advice from the experienced NCEC team in the event of a chemical emergency.

The agreement underpins the APAC Emergency Response initiative, which is due to start in January from OURAY’s new Singapore base, to provide a chemical response service for the Asia-Pacific region. The telephone emergency response (Level 1) will be carried out by NCEC’s best-in-class emergency response service. The on-site expert advice (Level 2) and the on-ground responder (Level 3) service will be provided by OURAY.

Jon Gibbard, Director of NCEC, said: “We have an experienced team of responders who are able to ask appropriate questions to understand the context of the scene, and alongside other sources of information such as SDSs, Chemdata and the responders’ own knowledge, they are able to give proportionate, actionable advice to the caller at the scene of the incident.”

Aaron Montgomery, CHMM/OURAY President and CEO, said: “OURAY is extremely excited about offering these combined services to the marketplace. This OURAY/NCEC partnership will allow our organisations to be the first in the world to provide combined Level 1, 2 and 3 services. This signifies a large step forward in OURAY’s mission to be a complete turn-key solution to the global chemical supply chain.”

Mr Gibbard said: “It is a great opportunity for NCEC/OURAY to support customers with best-in-class emergency response services within the Americas and Asia-Pacific region. We are excited to be working with OURAY. This holistic approach to emergency response further supports our vision to create a world fit for the future by reducing harm from incidents globally. This partnership is a clear indication of how NCEC’s advice-focused approach to emergency response is valued within the market. We are all looking forward to getting started.”

Information for editors

About NCEC

NCEC, part of Ricardo, is a leading provider of chemical emergency response and chemical regulatory support services, enabling customers to reduce the impact their activities have on people and the environment, while protecting their reputation and assets. Offering telephone emergency response, regulatory compliance and policy consultation and hazardous material (hazmat) training, NCEC is the first choice for some of the largest chemical companies across the globe. For more information, visit https://the-ncec.com/

About OURAY

OURAY is a leading and global environmental, engineering, manufacturing and chemical services company, offering solutions in over 100 countries. OURAY helps clients reach their long-term goals, by utilising its knowledge and experience across their global network to assist them with their most pressing needs.

https://www.OURAYservices.com/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye